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Abstract 
Objective: The inflammatory profile of chronic obstructive pulmonary disease (COPD) related to tobacco is known 
in certain studies while that of the post tuberculosis form is not yet known. This study aimed to evaluate the levels 
of neutrophils, macrophages and lymphocytes cells in sputum of COPD patients with history of smoking or anterior 
tuberculosis. Enumeration of cells in samples was analyzed using standard microscopy.
Results: We enrolled 92 participants, 46 (50%) were COPD subjects comprising 22 (47.83%) smokers and 24 (52.17%) 
with anterior tuberculosis while 46 (50%) healthy persons constituted the control group. The levels of neutrophils, 
lymphocytes and monocytes were statistically higher in COPD patients compared to the control group with p‑values 
of 0.0001 respectively. Neutrophils levels were higher in COPD patients with history of tobacco than in COPD patients 
with anterior tuberculosis with a mean rate of 4.72 × 106/ml and 2.48 × 106/ml respectively (p = 0.04). The monocytes 
and lymphocytes levels were not statistically different between the two sub‑groups of COPD patients with p‑value 
of 0.052 and 0.91 respectively. Neutrophils are the only inflammatory cells that were significantly higher in COPD 
patients with history of smoking as compared to COPD patients with anterior tuberculosis.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a dis-
ease affecting respiratory airways combining emphysema 
and chronic bronchitis [1]. According to the global ini-
tiative for obstructive lung diseases (GOLD), COPD will 
rise to the third most cause of death worldwide by 2020. 
The diagnosis is based on clinical assessment and spiro-
metric data including: forced expiratory volume (FEV), 
forced vital capacity (FVC), and FEV/FVC ratio. COPD 
is defined by the presence of irreversible obstruction 
ventilator trouble (OVT). Irreversible OVT is defined 
by a FEV/FVC ratio lower than 70% and the absence of 
a complete reversibility after inhalation of 400 μg of sal-
butamol [2]. The severity of COPD is evaluated based 
on the stages of GOLD: stage I, FEV > 80%; stage II, FEV 
between 50–80%; stage III, FEV between 30–50%; stage 
IV, FEV < 30% [3].
COPD is mainly caused by smoking and the inflam-
matory profile is known in developed countries [4]. The 
defense system of the respiratory airways consists of the 
mucociliary carpet and epithelial cells tight junctions 
which will be broken by chronic exposure to cigarette 
smoke that aggress it causing epithelial damage [5, 6]. 
These lesions linked to intoxication cause a local infiltra-
tion of neutrophiles, macrophage, and lymphocytes that 
release the mediators which act on the airways walls and 
induce fibrosis, increased muscle mass and airway wall 
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thickness, narrowing of airways, and causing limitation 
of respiratory flow [7]. These damages induce emphysema 
and chronic bronchitis that are peculiar of COPD [8, 9].
Although smoking is the main cause of COPD [10], 
anterior tuberculosis can also induce the disease. Dur-
ing tuberculosis, inflammation of the bronchial endothe-
lium induces: bronchial obstruction, pulmonary fibrosis, 
edema of airway mucosa, hypertrophy of the submucosal 
glands, which leads to airway limitation, main character-
istics of COPD [11, 12]; however, the inflammatory pro-
file of COPD in patients with history of tuberculosis is 
not yet known.
The use of anti-inflammatory drugs in the management 
of COPD may require knowledge of the inflammatory 
profile to adapt the treatment. The aim of this study was 
to evaluate the levels of neutrophils, macrophages and 
lymphocytes in COPD patients with history of smoking 
as compared to those with history of tuberculosis.
Main text
Methods
Participants were enrolled from March 2016 to April 
2017 at the Yaoundé Jamot Hospital (YJH); the main and 
biggest reference centre specialized in the management 
of pulmonary diseases. Participants comprised COPD 
patients and healthy participants that served as control. 
Age and sex of COPD patients were matched to con-
trols. COPD participants were patients consulting at the 
YJH and diagnosed by a pneumologist, comprising two 
sub-groups: COPD patients with a history of smoking 
(COPD/post tobacco) and COPD with a history of tuber-
culosis (COPD/post Tb). Sputum samples were collected 
from each participant and analyzed at the Center for the 
Study and Control of Communicable Diseases (CSCCD) 
of the Faculty of Medicine and Biomedical Sciences, Uni-
versity of Yaoundé I.
Once the pneumologist diagnosed a patient with 
COPD fulfilling the inclusion criteria, the spirometric 
results of these patients were extracted from their medi-
cal record. The history of tuberculosis or smoking was 
also extracted from their medical record and confirmed 
by each patient.
Spirometric measurements for the control group was 
done with the turbine pneumotachograph (care fusion) 
following the American Thoracic Society (ATS) standard 
of 2010 by an experienced nurse specialized in respira-
tory diseases and the results interpreted by the pneu-
mologist to ensure that these people do not have any 
respiratory problems.
Sputum was collected in a sterile container for neu-
trophils, macrophages and lymphocytes counts. Cell 
counts were performed after staining of the smear with 
May–Grunwald Giemsa (MGG) and read by standard 
microscopy.
This work was approved by the Cameroon National 
Ethical Committee of Research for Human Health (No 
2016/06/772/CE/CNERSH/SP). All participants gave 
their verbal and signed consent after receiving detailed 
information on the study.
Data for the study was entered into Microsoft Excel 
sheet and were analyzed with GraphPad PRISM version 
5.0 software (GraphPad Software, Inc., La Jolla, Cali-
fornia, USA). Chi square test was used to run statistical 
analysis for binary variables. Student t-test and its non 
parametric equivalent were used to compare means or 
median. p-values below 0.05 were considered statistically 
significant with a confidence interval (CI) of 95%.
Results
Demographic characteristics
A total of 92 participants comprising 42 (45%) male and 
50 (55%) female were included. Participants’ age ranged 
from 25 to 80  years. The enrollment consisted of 46 
COPD patients and 46 healthy persons for the control 
group. These 46 COPD patients comprised two sub-
groups: 22 COPD/post tobacco patients made up of 
20 (91%) males and 2 (9%) females, with a mean age of 
63 ± 10.45  years, and 24 COPD/post tuberculosis (Tb) 
patients made up of 8 (33.3%) males and 16 (66.7%) 
females with a mean age of 43 ± 12.38  years. A statisti-
cally significant difference was noted between the two 
COPD sub-groups with respect to sex and age with p-val-
ues of 0.0023 and 0.0002 respectively.
Clinical characteristics
Comparison of  FEV in  the  two sub‑groups of  COPD 
patients In COPD/post tobacco patients, the FEV 
ranged from 20.3 to 62.60% with an average of 36.88% 
(± 14.95%). For COPD/post Tb, the FEV varied from 30 
to 79% with an average of 53.30% (± 17.21%). The FEV was 
lower in COPD/post tobacco patients than in COPD/post 
Tb sub-group, p = 0.015.
Comparison of FEV/FVC ratio in two sub‑groups of COPD 
patients In COPD/post tobacco patients, the FEV/FVC 
ratio ranged from 36 to 68% with an average of 50.54% 
(± 12.09%). The FEV/FVC ratio of the COPD/post Tb 
varied from 36 to 72.35% with an average of 62.79% 
(± 17.95%). The FEV/FVC was lower in COPD/post 
tobacco than the COPD/post Tb sub-group, p = 0.033.
Comparison of COPD severity in patients (GOLD classifi‑
cation) In COPD/post tobacco patients, the stages were 
more advanced compare to COPD/post Tb. COPD/post 
tobacco sub-group comprised 11 (50%) stage IV, 6 (27.3%) 
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stage III and 5 (22.7%) stage II. COPD/post Tb comprised 
3 (12.5%) stage IV, 9 (37.5%) stage III and 12 (50%) stage 
II. A statistically significant difference was noted between 
the two sub-groups (p = 0.032).
Biological analysis of sputum
Determination of  neutrophils rates in  COPD and  con‑
trol The neutrophils rate (3.57 × 106 ± 3.8 × 106/ml) was 
statistically higher in COPD patients as compared to con-
trols (0.3 × 106 ± 0.12 × 106/ml) with p = 0.0001 (Fig. 1).
In the COPD/post tobacco sub-group, the neutro-
phils level (4.72 × 106 ± 4.89 × 106/ml) was statisti-
cally higher than those of COPD/post Tb (mean rate: 
2.48 × 106 ± 2.29 × 106/ml), p = 0.04 (Fig. 1).
Determination of  lymphocyte rate in  COPD and  con‑
trol The lymphocytes level of 3.38 × 106 ± 6.5 × 106/ml 
was higher in the COPD patients compared to those of 
control which was 0.10 × 106 ± 0.1 × 106/ml, p = 0.0001 
(Fig. 2).
In COPD/post tobacco patients, the lympho-
cytes rate (2.81 × 106 ± 4.4 × 106/ml) was not statisti-
cally different compared to those of COPD/post Tb 
(3.91 × 106 ± 8.07 × 106/ml), p = 0.91 (Fig. 2).
Determination of  monocytes counts in  COPD and  con‑
trol The monocytes count was statistically higher 
in COPD patients (1.90 × 106 ± 2.03 × 106/ml) com-
pare to the control group (0.14 × 106 ± 0.097 × 106/ml), 
p = 0.0001 (Fig. 3).
There was no statistically significant difference between 
the two COPD sub-group based on monocytes counts, 
p = 0.052 (Fig. 3).
Discussion
With respect to sex, males were predominant in the 
COPD/post tobacco sub-group compare to COPD/post 
Tb patients (p-value: 0.0023); suggesting that cultur-
ally fewer women actively smoked in the Cameroonian 
society.
COPD/post tobacco patients were older than COPD/
post Tb group (p = 0.0002). In several cases, tobacco 
smoking begins when people are already adult, and the 
airway tract is healthy. It is after several years of expo-
sure to cigarette smoke that COPD is established [13, 
14]. While tuberculosis can be contracted at any age 
(even childhood), which induces abnormal functioning 
of the airway tract especially obstructive airways com-
plications [15, 16] which can cause a rapid development 
of COPD.
The FEV percentage and FEV/FVC ratio were lower 
in COPD/post tobacco than in COPD/post Tb; con-
sequently, the COPD/post tobacco sub-group had 
COPD stages more severe than the stages of COPD/
post Tb sub-group. These results suggest that the 
perturbations and irritations caused by smoking are 
more pronounced than those induced by tuberculosis. 
Antituberculosis drugs kill mycobacterium and thus 
reduce the complications due to mycobacterium itself, 
whereas with smokers, cigarette smoking continues to 
damage until the establishment of COPD.
In sputum, the high levels of neutrophils, lympho-
cytes and monocytes in COPD patients when compared 
to the control group suggest that cellular inflamma-
tion in the airway tract is important during COPD. 
These results are comparable with other studies such as 
Gibson et  al., Casio et  al. and Profita et  al. who found 
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Fig. 1 Concentration of neutrophiles in COPD patients and in control 
group
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Fig. 2 Concentration of lymphocytes in COPD patients and in 
control group
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high levels of these cells in the airway tract of COPD 
patients compared to clinically healthy persons.
However, by comparing the two sub-groups of COPD 
patients, neutrophils rate were higher in COPD/post 
tobacco than COPD/post Tb (p = 0.04), indicating 
that neutrophils are more involved in COPD related 
to tobacco. Indeed, neutrophils are the main cellular 
marker of innate immunity during cigarette smoking 
because, they infiltrate into smokers airway tract before 
advancement to COPD [17]. Neutrophils are attracted 
into the airway tract by the intoxication induced by 
cigarette smoking. Neutrophils secrete substances like 
5-hydroxy-eicosanotetraenoic acid, Leukotriene B4 
(which contribute to the chemotactic activity of expec-
torations), myeloperoxidase (which activates the secre-
tion of interleukin-8), elastase (which cases the elasticity 
loss of elastic fiber and promote epithelial cells to pro-
duce more IL-8 and Leukotriene B4). Neutrophils also 
produce IL-1 which contributes in leukocytosis activity 
and in the production of other cytokines [17, 18].
The levels of monocytes and lymphocytes were simi-
lar in the two groups of COPD patients with p-value of 
0.052 and 0.91 respectively suggesting that these cells 
act at the same level in both forms of COPD.
Monocytes/macrophages in COPD caused by 
tobacco smoking produce proteins of the extracellular 
matrix, lipid mediators, Leukotriene, prostaglandines, 
cytokines, chemokines and the metalloproteinase 
matrix (MMP), these substances are associated in 
both fibrosis of the small airways and to centrilobular 
emphysema in COPD. In culture, monocytes of smok-
ers and those of COPD patients release an important 
rate of MMP-1 and 9, IL-6 and the monocyte chemot-
actic protein-1 (MCP-1) [18, 19].
Looking at lymphocytes, CD8 T-lymphocytes play an 
important role in inflammation and the development of 
emphysema by producing Interferon gamma (IFN- ϒ), 
interferon-inducible protein-10 (IP-10) and monokine 
induced by interferon-gamma (MIG). These products 
promote the secretion of MMP and chemokine (IL-8 and 
MCP-1) by macrophages [20]. The actions of these sub-
stances on the endothelial cells make them change and 
remodel their membrane favoring the macromolecules 
lost and cellular extravasations. CD8 T lymphocytes 
also have a role in the development of COPD because 
the cytotoxic activity of CD8 is more pronounced due 
to the secretion of perforin and granzymes which lyses 
pulmonary parenchyma cells [21]. CD8 lymphocyte also 
expresses as which lead to apoptosis of the epithelial and 
endothelial cell. The principal function of CD8 cells is to 
eliminate infected cells by cytolysis or by apoptosis [22].
B cells in COPD generally reflect both an adaptive 
response against chronic infections in the advanced COPD 
or as auto-immune response originally induced by auto-
antibodies [21]. Approximately 70% of COPD patients 
have Ig-G auto-antibodies circulating against epithelial 
cell [21]. The auto-immune mechanism in chronic inflam-
mation and emphysematous damage are justified by the 
detection of circulating auto-antibodies against undam-
aged proteins. These auto-antibodies are mainly anti-
elastin and anti-epithelial in smokers COPD. Contrarily 
to COPD related to tobacco, studies on COPD caused by 
tuberculosis have shown several risks conducive to COPD 
[23, 24] but, have not decrypted the relation between the 
pathogenesis of the diseases and the inflammation.
Conclusion
We therefore conclude that the pathogenesis of COPD/
post Tb could be associated with pulmonary neutrophilic 
polynucleosis, monocytosis and lymphocytosis same as 
in COPD/post tobacco, with a higher level of neutrophils 
in COPD/post tobacco.
Limitation
The main strength of this study was that it was done in a 
resource limited setting in which the prevalence of Tb is 
high with an important incidence of post Tb pulmonary 
obstruction where limited studies have been carried out. 
A limit of this study was that we did not distinguish the 
levels of T lymphocytes from B lymphocytes.
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